Free Trial
NASDAQ:EPRX

Eupraxia Pharmaceuticals (EPRX) Stock Price, News & Analysis

Eupraxia Pharmaceuticals logo
$5.29 -0.12 (-2.22%)
Closing price 07/18/2025 03:50 PM Eastern
Extended Trading
$5.34 +0.05 (+0.95%)
As of 07/18/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Eupraxia Pharmaceuticals Stock (NASDAQ:EPRX)

Key Stats

Today's Range
$5.26
$5.38
50-Day Range
$3.79
$5.84
52-Week Range
$2.20
$6.20
Volume
4,195 shs
Average Volume
13,482 shs
Market Capitalization
$190.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00
Consensus Rating
Buy

Company Overview

Receive EPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eupraxia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EPRX Stock News Headlines

[No Brainer Gold Play]: “Show me a better investment.”
A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
Eupraxia Pharma director buys as stock tests top of range
See More Headlines

EPRX Stock Analysis - Frequently Asked Questions

Eupraxia Pharmaceuticals' stock was trading at $3.17 at the beginning of 2025. Since then, EPRX stock has increased by 66.9% and is now trading at $5.29.

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) announced its quarterly earnings results on Tuesday, May, 6th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by $0.02.

Shares of EPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Eupraxia Pharmaceuticals investors own include Aeterna Zentaris (AEZS), BlackBerry (BB), Bausch Health Cos (BHC), Bitfarms (BITF), Ballard Power Systems (BLDP), Cardiol Therapeutics (CRDL) and Fury Gold Mines (FURY).

Company Calendar

Last Earnings
5/06/2025
Today
7/18/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:EPRX
Previous Symbol
NASDAQ:EPRX
CIK
1581178
Fax
N/A
Employees
29
Year Founded
N/A

Price Target and Rating

High Price Target
$12.00
Low Price Target
$9.00
Potential Upside/Downside
+107.9%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.76)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$25.50 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-367.73%
Return on Assets
-112.23%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
11.10
Quick Ratio
11.10

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
35,960,000
Free Float
N/A
Market Cap
$190.23 million
Optionable
N/A
Beta
1.55
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:EPRX) was last updated on 7/19/2025 by MarketBeat.com Staff
From Our Partners